Development and internal validation of the male osteoporosis risk estimation score

Angela Shepherd, Alvah R. Cass, Carol A. Carlson, Laura Ray

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

PURPOSE: We wanted to develop and validate a clinical prediction rule to identify men at risk for osteoporosis and subsequent hip fracture who might benefit from dual-energy x-ray absorptiometry (DXA). METHODS: We used risk factor data from the National Health and Nutrition Examination Survey III to develop a best fitting multivariable logistic regression model in men aged 50 years and older randomized to either the development (n = 1,497) or validation (n = 1,498) cohorts. The best fitting model was transformed into a simplified scoring algorithm, the Male Osteoporosis Risk Estimation Score (MORES). We validated the MORES, comparing sensitivity, specificity, and area under the receiver operating characteristics (ROC) curve in the 2 cohorts and assessed clinical utility with an analysis of the number needed-to-screen (NNS) to prevent 1 additional hip fracture. RESULTS: The MORES included 3 variables - age, weight, and history of chronic obstructive pulmonary disease - and showed excellent predictive validity in the validation cohort. A score of 6 or greater yielded an overall sensitivity of 0.93 (95% CI, 0.85-0.97), a specificity of 0.59 (95% CI, 0.56-0.62), and an area under the ROC curve of 0.832 (95% CI, 0.807-0.858). The overall NNS to prevent 1 additional hip fracture was 279 in a cohort of men representative of the US population. CONCLUSIONS: Osteoporosis is a major predictor of hip fractures. Experts believe bisphosphonate treatment in men should yield results similar to that in women and reduce hip fracture rates associated with osteoporosis. In men aged 60 years and older, the MORES is a simple approach to identify men at risk for osteoporosis and refer them for confirmatory DXA scans.

Original languageEnglish (US)
Pages (from-to)540-546
Number of pages7
JournalAnnals of Family Medicine
Volume5
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Osteoporosis
Hip Fractures
ROC Curve
Logistic Models
X-Rays
Decision Support Techniques
Nutrition Surveys
Diphosphonates
Chronic Obstructive Pulmonary Disease
Weights and Measures
Sensitivity and Specificity
Population

Keywords

  • Bone density
  • Men's health
  • Osteoporosis

ASJC Scopus subject areas

  • Family Practice

Cite this

Development and internal validation of the male osteoporosis risk estimation score. / Shepherd, Angela; Cass, Alvah R.; Carlson, Carol A.; Ray, Laura.

In: Annals of Family Medicine, Vol. 5, No. 6, 11.2007, p. 540-546.

Research output: Contribution to journalArticle

Shepherd, Angela ; Cass, Alvah R. ; Carlson, Carol A. ; Ray, Laura. / Development and internal validation of the male osteoporosis risk estimation score. In: Annals of Family Medicine. 2007 ; Vol. 5, No. 6. pp. 540-546.
@article{b79bcd7b7d0e4fd1b1e4619909cbf044,
title = "Development and internal validation of the male osteoporosis risk estimation score",
abstract = "PURPOSE: We wanted to develop and validate a clinical prediction rule to identify men at risk for osteoporosis and subsequent hip fracture who might benefit from dual-energy x-ray absorptiometry (DXA). METHODS: We used risk factor data from the National Health and Nutrition Examination Survey III to develop a best fitting multivariable logistic regression model in men aged 50 years and older randomized to either the development (n = 1,497) or validation (n = 1,498) cohorts. The best fitting model was transformed into a simplified scoring algorithm, the Male Osteoporosis Risk Estimation Score (MORES). We validated the MORES, comparing sensitivity, specificity, and area under the receiver operating characteristics (ROC) curve in the 2 cohorts and assessed clinical utility with an analysis of the number needed-to-screen (NNS) to prevent 1 additional hip fracture. RESULTS: The MORES included 3 variables - age, weight, and history of chronic obstructive pulmonary disease - and showed excellent predictive validity in the validation cohort. A score of 6 or greater yielded an overall sensitivity of 0.93 (95{\%} CI, 0.85-0.97), a specificity of 0.59 (95{\%} CI, 0.56-0.62), and an area under the ROC curve of 0.832 (95{\%} CI, 0.807-0.858). The overall NNS to prevent 1 additional hip fracture was 279 in a cohort of men representative of the US population. CONCLUSIONS: Osteoporosis is a major predictor of hip fractures. Experts believe bisphosphonate treatment in men should yield results similar to that in women and reduce hip fracture rates associated with osteoporosis. In men aged 60 years and older, the MORES is a simple approach to identify men at risk for osteoporosis and refer them for confirmatory DXA scans.",
keywords = "Bone density, Men's health, Osteoporosis",
author = "Angela Shepherd and Cass, {Alvah R.} and Carlson, {Carol A.} and Laura Ray",
year = "2007",
month = "11",
doi = "10.1370/afm.753",
language = "English (US)",
volume = "5",
pages = "540--546",
journal = "Annals of Family Medicine",
issn = "1544-1709",
publisher = "Annals of Family Medicine, Inc",
number = "6",

}

TY - JOUR

T1 - Development and internal validation of the male osteoporosis risk estimation score

AU - Shepherd, Angela

AU - Cass, Alvah R.

AU - Carlson, Carol A.

AU - Ray, Laura

PY - 2007/11

Y1 - 2007/11

N2 - PURPOSE: We wanted to develop and validate a clinical prediction rule to identify men at risk for osteoporosis and subsequent hip fracture who might benefit from dual-energy x-ray absorptiometry (DXA). METHODS: We used risk factor data from the National Health and Nutrition Examination Survey III to develop a best fitting multivariable logistic regression model in men aged 50 years and older randomized to either the development (n = 1,497) or validation (n = 1,498) cohorts. The best fitting model was transformed into a simplified scoring algorithm, the Male Osteoporosis Risk Estimation Score (MORES). We validated the MORES, comparing sensitivity, specificity, and area under the receiver operating characteristics (ROC) curve in the 2 cohorts and assessed clinical utility with an analysis of the number needed-to-screen (NNS) to prevent 1 additional hip fracture. RESULTS: The MORES included 3 variables - age, weight, and history of chronic obstructive pulmonary disease - and showed excellent predictive validity in the validation cohort. A score of 6 or greater yielded an overall sensitivity of 0.93 (95% CI, 0.85-0.97), a specificity of 0.59 (95% CI, 0.56-0.62), and an area under the ROC curve of 0.832 (95% CI, 0.807-0.858). The overall NNS to prevent 1 additional hip fracture was 279 in a cohort of men representative of the US population. CONCLUSIONS: Osteoporosis is a major predictor of hip fractures. Experts believe bisphosphonate treatment in men should yield results similar to that in women and reduce hip fracture rates associated with osteoporosis. In men aged 60 years and older, the MORES is a simple approach to identify men at risk for osteoporosis and refer them for confirmatory DXA scans.

AB - PURPOSE: We wanted to develop and validate a clinical prediction rule to identify men at risk for osteoporosis and subsequent hip fracture who might benefit from dual-energy x-ray absorptiometry (DXA). METHODS: We used risk factor data from the National Health and Nutrition Examination Survey III to develop a best fitting multivariable logistic regression model in men aged 50 years and older randomized to either the development (n = 1,497) or validation (n = 1,498) cohorts. The best fitting model was transformed into a simplified scoring algorithm, the Male Osteoporosis Risk Estimation Score (MORES). We validated the MORES, comparing sensitivity, specificity, and area under the receiver operating characteristics (ROC) curve in the 2 cohorts and assessed clinical utility with an analysis of the number needed-to-screen (NNS) to prevent 1 additional hip fracture. RESULTS: The MORES included 3 variables - age, weight, and history of chronic obstructive pulmonary disease - and showed excellent predictive validity in the validation cohort. A score of 6 or greater yielded an overall sensitivity of 0.93 (95% CI, 0.85-0.97), a specificity of 0.59 (95% CI, 0.56-0.62), and an area under the ROC curve of 0.832 (95% CI, 0.807-0.858). The overall NNS to prevent 1 additional hip fracture was 279 in a cohort of men representative of the US population. CONCLUSIONS: Osteoporosis is a major predictor of hip fractures. Experts believe bisphosphonate treatment in men should yield results similar to that in women and reduce hip fracture rates associated with osteoporosis. In men aged 60 years and older, the MORES is a simple approach to identify men at risk for osteoporosis and refer them for confirmatory DXA scans.

KW - Bone density

KW - Men's health

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=37049021793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049021793&partnerID=8YFLogxK

U2 - 10.1370/afm.753

DO - 10.1370/afm.753

M3 - Article

VL - 5

SP - 540

EP - 546

JO - Annals of Family Medicine

JF - Annals of Family Medicine

SN - 1544-1709

IS - 6

ER -